Abstract
Oral fingolimod (Gilenya) is a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes. Fingolimod reduces relapses and delays disability progression in patients with relapsing forms of multiple sclerosis (MS). We report a patient with MS who developed asystole and sustained bradycardia 21 hours after the first dose of fingolimod.
Get full access to this article
View all access options for this article.
References
1.
Kappos
L
Radue
EW
O’Connor
P
. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis . N Engl J Med 2010 ; 362 : 387 –401 .
2.
Cohen
JA
Barkhof
F
Comi
G
. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis . N Engl J Med 2010 ; 362 : 402 –415 .
3.
Kovarik
JM
Schmouder
R
Barilla
D
Wang
Y
Kraus
G
. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects . Br J Clin Pharmacol 2004 ; 57 : 586 –591 .
4.
Smiler
B
. Risperidol and asystole . Anesth Analg 2004 ; 99 : 623 .
5.
Alvarez
PA
Pahissa
J
. QT alterations in psychopharmacology: proven candidates and suspects . Curr Drug Saf 2010 ; 5 : 97 –104 .
6.
Marti
V
. Sudden cardiac death due to risperidone therapy in a patient with possible hypertrophic cardiomyopathy . Ann Pharmacother 2005 ; 39 : 973
7.
Ravin
DS
Levenson
JW
. Fatal cardiac event following initiation of risperidone therapy . Ann Pharmacother 1997 ; 31 : 867 –870